Cipla Limited - Asset Resilience Ratio

Latest as of September 2025: 20.75%

Cipla Limited (CIPLA) has an Asset Resilience Ratio of 20.75% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Cipla Limited strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Rs83.35 Billion
≈ $901.43 Million USD Cash + Short-term Investments

Total Assets

Rs401.64 Billion
≈ $4.34 Billion USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2004–2025)

This chart shows how Cipla Limited's Asset Resilience Ratio has changed over time. See Cipla Limited net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Cipla Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CIPLA stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs7.96 Billion 1.98%
Short-term Investments Rs75.39 Billion 18.77%
Total Liquid Assets Rs83.35 Billion 20.75%

Asset Resilience Insights

  • Good Liquidity Position: Cipla Limited maintains a healthy 20.75% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Cipla Limited Industry Peers by Asset Resilience Ratio

Compare Cipla Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Aurobindo Pharma Limited
NSE:AUROPHARMA
Drug Manufacturers - Specialty & Generic 1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
Drug Manufacturers - Specialty & Generic -0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
Drug Manufacturers - Specialty & Generic 0.20%
Xeris Pharmaceuticals Inc
NASDAQ:XERS
Drug Manufacturers - Specialty & Generic 0.00%
Procter & Gamble Health Limited
NSE:PGHL
Drug Manufacturers - Specialty & Generic 33.01%

Annual Asset Resilience Ratio for Cipla Limited (2004–2025)

The table below shows the annual Asset Resilience Ratio data for Cipla Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 26.83% Rs100.32 Billion
≈ $1.08 Billion
Rs373.87 Billion
≈ $4.04 Billion
+4.93pp
2024-03-31 21.90% Rs71.65 Billion
≈ $774.91 Million
Rs327.18 Billion
≈ $3.54 Billion
+2.49pp
2023-03-31 19.41% Rs57.19 Billion
≈ $618.51 Million
Rs294.63 Billion
≈ $3.19 Billion
+4.58pp
2022-03-31 14.83% Rs40.19 Billion
≈ $434.67 Million
Rs271.01 Billion
≈ $2.93 Billion
+2.49pp
2021-03-31 12.34% Rs31.03 Billion
≈ $335.55 Million
Rs251.52 Billion
≈ $2.72 Billion
+10.48pp
2020-03-31 1.86% Rs4.39 Billion
≈ $47.52 Million
Rs236.63 Billion
≈ $2.56 Billion
+1.32pp
2019-03-31 0.53% Rs1.28 Billion
≈ $13.86 Million
Rs239.63 Billion
≈ $2.59 Billion
-0.07pp
2018-03-31 0.61% Rs1.39 Billion
≈ $15.05 Million
Rs228.61 Billion
≈ $2.47 Billion
+0.55pp
2017-03-31 0.06% Rs118.30 Million
≈ $1.28 Million
Rs210.37 Billion
≈ $2.28 Billion
-2.71pp
2016-03-31 2.77% Rs5.85 Billion
≈ $63.26 Million
Rs211.28 Billion
≈ $2.28 Billion
+0.29pp
2015-03-31 2.48% Rs3.90 Billion
≈ $42.18 Million
Rs157.18 Billion
≈ $1.70 Billion
-0.43pp
2014-03-31 2.91% Rs3.90 Billion
≈ $42.18 Million
Rs134.03 Billion
≈ $1.45 Billion
-15.25pp
2013-03-31 18.16% Rs21.17 Billion
≈ $228.92 Million
Rs116.59 Billion
≈ $1.26 Billion
+8.10pp
2012-03-31 10.06% Rs9.41 Billion
≈ $101.71 Million
Rs93.50 Billion
≈ $1.01 Billion
+7.46pp
2011-03-31 2.60% Rs2.24 Billion
≈ $24.18 Million
Rs85.97 Billion
≈ $929.70 Million
+2.59pp
2010-03-31 0.01% Rs5.20 Million
≈ $56.24K
Rs73.09 Billion
≈ $790.45 Million
-13.04pp
2009-03-31 13.05% Rs8.95 Billion
≈ $96.78 Million
Rs68.57 Billion
≈ $741.53 Million
-6.20pp
2008-03-31 19.25% Rs11.03 Billion
≈ $119.33 Million
Rs57.33 Billion
≈ $619.96 Million
+4.05pp
2007-03-31 15.20% Rs6.71 Billion
≈ $72.56 Million
Rs44.14 Billion
≈ $477.33 Million
+3.59pp
2006-03-31 11.61% Rs4.01 Billion
≈ $43.42 Million
Rs34.58 Billion
≈ $374.01 Million
-3.36pp
2005-03-31 14.97% Rs3.91 Billion
≈ $42.28 Million
Rs26.12 Billion
≈ $282.50 Million
-0.43pp
2004-03-31 15.40% Rs3.42 Billion
≈ $36.98 Million
Rs22.20 Billion
≈ $240.10 Million
--
pp = percentage points

About Cipla Limited

NSE:CIPLA India Drug Manufacturers - Specialty & Generic
Market Cap
$12.00 Billion
Rs1.11 Trillion INR
Market Cap Rank
#1984 Global
#75 in India
Share Price
Rs1373.20
Change (1 day)
-0.59%
52-Week Range
Rs1192.40 - Rs1663.60
All Time High
Rs1683.00
About

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, suc… Read more